Neurometrix (NURO) Shares Gap Up to $2.07

Neurometrix Inc (NASDAQ:NURO)’s share price gapped up prior to trading on Friday . The stock had previously closed at $2.01, but opened at $2.07. Neurometrix shares last traded at $2.08, with a volume of 2192100 shares trading hands.

Several equities analysts have recently commented on the company. ValuEngine raised Neurometrix from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 26th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price (down previously from $10.00) on shares of Neurometrix in a research report on Friday, October 20th.

The stock has a market capitalization of $4.86, a PE ratio of -0.12 and a beta of 0.32.

Neurometrix (NASDAQ:NURO) last issued its quarterly earnings results on Friday, October 20th. The medical device company reported ($3.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.60) by ($1.51). Neurometrix had a negative return on equity of 232.71% and a negative net margin of 80.57%.

TRADEMARK VIOLATION WARNING: “Neurometrix (NURO) Shares Gap Up to $2.07” was first published by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.thestockobserver.com/2018/01/19/neurometrix-nuro-shares-gap-up-to-2-07.html.

About Neurometrix

NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.

Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply